Immunotherapy in ovarian cancer: we are not there yet
E Barber, D Matei - The Lancet Oncology, 2021 - thelancet.com
E Barber, D Matei
The Lancet Oncology, 2021•thelancet.com2 Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation
therapy fractionation for bone metastases. Radiother Oncol 2018; 126: 547–57. 3 Sahgal A,
Myrehaug SD, Siva S, et al. Stereotactic body radiotherapy versus conventional external
beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre,
randomised, controlled, phase 2/3 trial. Lancet Oncol 2021; published online June 11.
https://doi. org/10.1016/S1470-2045 (21) 00196-0. 4 Sprave T, Verma V, Förster R, et al …
therapy fractionation for bone metastases. Radiother Oncol 2018; 126: 547–57. 3 Sahgal A,
Myrehaug SD, Siva S, et al. Stereotactic body radiotherapy versus conventional external
beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre,
randomised, controlled, phase 2/3 trial. Lancet Oncol 2021; published online June 11.
https://doi. org/10.1016/S1470-2045 (21) 00196-0. 4 Sprave T, Verma V, Förster R, et al …
2 Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol 2018; 126: 547–57. 3 Sahgal A, Myrehaug SD, Siva S, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol 2021; published online June 11. https://doi. org/10.1016/S1470-2045 (21) 00196-0.
4 Sprave T, Verma V, Förster R, et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol 2018; 128: 274–82. 5 Nguyen QN, Chun SG, Chow E, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol 2019; 5: 872–78.
thelancet.com